

# Division of Workers' Compensation Pharmacy and Therapeutics Committee

April 24, 2019  
12:30pm to 2:30pm



State of California  
Gavin Newsom  
Governor

# Agenda

- **Welcome and Introductions**

George Parisotto, Administrative Director, DWC

- **Approval of Minutes from the January 23, 2019 Meeting**

Dr. Raymond Meister, Executive Medical Director, DWC

- **Discussion:**

- Drug Review Process

*Raymond Tan, Pharm.D., Zenith Insurance Company*

*Kevin Gorospe, DWC Consultant*

- Drug Review – naloxone

*Raymond Tan, Pharm.D.*

- Category Review – NSAIDs

*Kevin Gorospe, Pharm.D. DWC Consultant*

- **Public Comments**

- **Review of Committee Recommendations**

- **Adjourn**



# Welcome and Introductions

George Parisotto

Administrative Director, DWC

# Approval of Minutes

Dr. Raymond Meister

Executive Medical Director, DWC

# Drug Reviews

J. Kevin Gorospe, Pharm.D.  
DWC Consultant

Raymond Tan, PharmD  
AVP Medical Management-Pharmacy, Zenith Insurance Co.  
Committee Member

# Drug Product Reviews

- Process for review
  - Individual drugs
  - Category of drugs
- Key comparative considerations
  - Efficacy
  - Safety
  - Misuse Potential
  - Cost

# Cost Factor

- Weighing the four primary considerations
- Cost comparison between products
  - Typical (average) prescription size (i.e. number of units - tablets, capsules, etc.) is important
  - Comparative Cost = # of Units x Unit Cost
  - Dispensing fee only a factor if there is a difference in numbers of prescriptions dispensed to reach same treatment outcome
- When should cost matter?
  - Balance of factors, or
  - Only when efficacy, safety and misuse are relatively equal

# MTUS Formulary Detail

- Committee recommendations will
  - Identify drug/dosage form/strength combinations that should be on MTUS Formulary
  - Identify Exempt status for each drug/dosage form/strength
  - Identify potential changes to other status values (i.e. Special Fill or Peri-Op)
- DWC will review recommendations for actions
- DWC will identify Unique Pharmaceutical Identifier (i.e. RxCUI) for all drugs retained on the MTUS Formulary

# Initial Effort

- Both types of reviews during this meeting
- Single Drug Review
  - naloxone
- Category Review
  - NSAIDs
- Discussion to follow
  - Next drugs/categories to consider – how to choose
  - Value of information presented
  - Process recommendations
  - Information members like, dislike, additional needs

# Individual Drug Review – Naloxone

Raymond Tan, PharmD

AVP Medical Management-Pharmacy, Zenith Insurance Co.  
Committee Member

# Naloxone

- Competitive opiate antagonist
- Listed on MTUS Formulary as “naloxone hcl”
  - Generic Name – naloxone hydrochloride
  - Reference Brand(s) – Narcan; Evzio
  - Drug Class – Antidotes and Specific Antagonists
  - Dosage form/route of administration – injectable solution; nasal solution
- Rescue treatment for opioid overdose
- Status – “Exempt”

# Marketed Products

MTUS Drug Ingredient	Generic Name	Reference Brand Name	Exempt/Non-Exempt*	Special Fill	Peri-Op	Drug Class	Dosage Form	Strength	RxCUI
naloxone hcl	naloxone hdrochloride	Narcan	Exempt			Antidotes and Specific Antagonists	prefilled syringe, 2 ml	0.4 mg/ml	1191245
naloxone hcl	naloxone hdrochloride	Narcan	Exempt			Antidotes and Specific Antagonists	prefilled syringe, 2 ml	1 mg/ml	1191250
naloxone hcl	naloxone hdrochloride	Evzio	Exempt			Antidotes and Specific Antagonists	injection im/sc	2 mg/ 0.4ml	1855730
naloxone hcl	naloxone hdrochloride	Narcan	Exempt			Antidotes and Specific Antagonists	nasal; 4 mg/spray	40 mg/ml	1725059

- Prefilled syringes not good choices for patient self-administration; designed for medical professional use
- Evzio injection and Narcan nasal designed for patient use

# Naloxone Product Comparison

- Both available as brand name drug only
- Dosage form/strength
  - Narcan – 4mg/0.1ml nasal spray (2 doses per container)
  - Evzio – 2mg/0.4ml autoinjector (2 doses per container)
- Efficacy
  - In pharmacokinetic studies, both demonstrated bioequivalence with a previously approved formulation & sufficient plasma exposure in first 15-20 minutes after administration to reverse an opioid overdose
- Safety – No significant difference between products
- Ease of Use
  - Studies indicate more than 90% of patients have no problems using either product
  - Nasal product has limitations in individuals that have nasal pathologies

# Cost Comparisons

NDC	Product Name	Current Medi-Cal Rate	NADAC	WAC
60842-0051-01	EVZIO 2MG AutoInjector (2 doses)	\$ 4,100.00	n/a	\$ 4,100.00
69547-0353-02	NARCAN 4 MG Nasal Spray (2 doses)	\$ 119.65	\$ 119.65	\$ 125.00

# Committee Discussion

- Naloxone Considerations
  - Exclusion of non-patient friendly dosage forms on the MTUS Formulary
  - Potential change in exempt status for Evzio
    - Efficacy, safety, use similar/same to Narcan
    - Cost is 17 times higher than Narcan
    - Consideration for patients with nasal or other pathology that would inhibit use of Narcan
- Other discussion points / items to consider

# Non-Steroidal Anti-Inflammatory Drugs

J. Kevin Gorospe, PharmD

DWC Consultant

# Non-Steroidal Anti-Inflammatory Drugs

- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  - One of the most commonly used classes of drugs to treat pain and inflammation
  - Among the top 50 drugs by total reimbursement under the workers compensation program
- Broad use can be attributable to over-the-counter availability - ibuprofen, naproxen, and naproxen sodium are among the most used OTC pain medications
- NSAIDs exhibit analgesic, anti-inflammatory, and antipyretic effects
- Mechanism of action is by inhibiting the enzymatic action of cyclooxygenase (COX) which exists in two forms COX-1 and COX-2
  - COX-2 is the enzyme responsible for inflammation and fever
  - COX-1 serves to protect the gastric mucosa and assists in making platelets stick together

# NSAIDs

- The NSAID class consists of
- non-selective COX inhibitors (e.g. naproxen and ibuprofen)
- partially selective inhibitors that favor COX-2 over COX-1 (e.g. meloxicam and nabumetone)
- selective COX-2 inhibitor celecoxib (Celebrex)
- NSAIDs are typically grouped into sub-classifications
- For this review the drugs have been grouped as follows

# NSAIDs Sub-Classifications

## ACETIC ACID DERIVATIVES

diclofenac

diclofenac potassium

diclofenac sodium

diclofenac sodium/misoprostol

etodolac

indomethacin

ketorolac tromethamine

sulindac

tolmetin sodium

## ANTHRANILIC ACID DERIVATIVES

meclofenamate sodium

mefenamic acid

## ENOLIC ACID (OXICAM) DERIVATIVES

meloxicam

piroxicam

## COX-2 INHIBITORS

celecoxib

## BROMINATED OXO MONOCARBOXYLIC ACID

bromfenac sodium

## CARBOXYLIC ACID DERIVATIVES

diflunisal

salsalate

## SALICYLATES/MISCELLANEOUS

aspirin

choline magnesium trisalicylate

## NAPHTHYLALKANONE DERIVATIVES

nabumetone

## PROPRIONIC ACID DERIVATIVES

esomeprazole/naproxen

famotidine/ibuprofen

fenoprofen calcium

flurbiprofen

flurbiprofen sodium

ibuprofen

ketoprofen

naproxen

naproxen sodium

oxaprozin

# General Observations

- NSAIDs have been reviewed by multiple groups such as Oregon Health & Science University and University of Massachusetts Medical School
- The in-depth reviews generally conclude that NSAIDs
  - are relatively safe, though they have Black Box warnings regarding the increased risk of GI adverse reactions and cardiovascular risks
  - no significant short-term differences between oral NSAIDs for pain relief
  - celecoxib, being a COX-2 specific agent, is not associated with higher risk of cardiovascular events when compared to other NSAIDs
  - celecoxib and nabumetone are more gastroprotective than other NSAIDs
- Reviews also note that age, history of GI events, use of other drugs such as antiulcer medication, and other adverse events also seen with NSAIDs use are important when considering use of NSAIDs in a patient

# MDGuidelines – Supporting Evidence

- Evidence for use is based on a combination of identified condition (injury) and drugs used to treat the condition
- There are 15 categories (areas of body) each having various conditions listed
- Under each condition, drugs used for the condition are listed showing:
  - The phase of treatment – Acute or Chronic
  - Pain Classification – e.g. Post-operative, Subacute
  - Drug Classification – e.g. Analgesics – Anti-Inflammatory
  - Drug Name – e.g. celecoxib (Celebrex)
  - Evidence Support – the strength of the evidence – e.g. Yes, Limited Evidence (C)

# Strength of Evidence

- Yes, Strong Evidence, "A" Level Evidence
  - Yes, Moderate Evidence, "B" Level Evidence
  - Yes, Limited Evidence, "C" Level Evidence
  - Yes, Insufficient Evidence (Consensus-based), "I" Level
  - Yes, Other = Recommended, Healthe systems recommendations based on leading sources as well as P&T decisions (pharmacy and medical literature, safety, cost)
  - No Recommendation
- No, Strong Evidence, "A" Level Evidence
  - No, Moderate Evidence, "B" Level Evidence
  - No, Limited Evidence, "C" Level Evidence
  - No, Insufficient Evidence (Consensus-based), "I" Level
  - No, Other = Not Recommended, Healthe systems recommendations based on leading sources as well as pharmacy and therapeutics (P&T) decisions (pharmacy and medical literature, safety, cost)

# NSAIDs Evidence

- Each drug under review was identified for each Condition and the strength of evidence was noted
- Color coded charts of the drugs and strength of evidence were provided to P&T members as a guide, however the MDGuidelines Formulary Tool was utilized to perform more detailed analysis
- The evidence for use was generally homogeneous across almost all of the NSAIDs
- The exceptions were ketorolac tromethamine, piroxicam, and the combination products esomeprazole/naproxen and famotidine/ibuprofen which were rated “No, Other” for almost every condition identified for NSAIDs use

Category		Ankle and Foot Disorders											
Condition		Achilles Tendinopathy		Achilles Tendon Rupture		Ankle and Foot Fractures		Ankle Sprain		Ankle Tendinopathy - Tendinopathy other than Achilles		Charcot Joint	
Phase		Acute	Chronic	Acute	Chronic	Acute	Chronic	Acute	Chronic	Acute	Chronic	Acute	Chronic
aspirin	Exempt					I		I					
bromfenac sodium	Exempt												
celecoxib	Exempt	C	I	I	I	I		A	I	I	I	I	I
choline magnesium trisalicylate	Exempt	C	I	I	I	I		A	I	I	I	I	I
diclofenac													
diclofenac potassium	Exempt	C	I	I	I	I		A	I	I	I	I	I
diclofenac sodium	Exempt†												
diclofenac sodium/misoprostol	Exempt									I	I	I	I
diflunisal	Exempt	C	I	I	I	I		A	I	I	I	I	I
esomeprazole/naproxen	Non-Exempt	NO	NO	NO	NO	NO		NO	NO	NO	NO	NO	NO
etodolac	Exempt	C	I	I	I	I		A	I	I	I	I	I
famotidine/ibuprofen	Non-Exempt	NO	NO	NO	NO	NO		NO	NO	NO	NO	NO	NO
fenoprofen calcium	Exempt	C	I	I	I	I		A	I	I	I	I	I
flurbiprofen	Exempt	C	I	I	I	I		A	I	I	I	I	I
flurbiprofen sodium	Exempt												
ibuprofen	Exempt	C	I	I	I	I		A	I	I	I	I	I
indomethacin	Exempt	C	I	I	I	I		A	I	I	I	I	I
ketoprofen	Exempt	C	I	I	I	I		A	I	I	I	I	I
ketorolac tromethamine	Exempt†	NO	NO	NO	NO	NO		NO	NO	NO	NO	NO	NO
meclofenamate sodium	Exempt	C	I	I	I	I		A	I	I	I	I	I
mefenamic acid	Exempt	C	I	I	I	I		A	I	I	I	I	I
meloxicam	Exempt	C	I	I	I	I		A	I	I	I	I	I
nabumetone	Exempt	C	I	I	I	I		A	I	I	I	I	I
naproxen	Exempt	C/NR*	I/NR*	I	I	I		A	I	I	I	I	I
naproxen sodium													
oxaprozin	Exempt	C	I	I	I	I		A	I	I	I	I	I
piroxicam	Non-Exempt	NO	NO	NO	NO	NO		NO	NO	NO	NO	NO	NO
salsalate	Exempt	C	I	I	I	I		A	I	I	I	I	I
sulindac	Exempt	C	I	I	I	I		A	I	I	I	I	I
tolmetin sodium	Exempt	C	I	I	I	I		A	I	I	I	I	

† = Ophthalmic form Exempt; Oral form Non-Exempt

Category		Ankle and Foot Disorders											
Condition		Achilles Tendinopathy		Achilles Tendon Rupture		Ankle and Foot Fractures		Ankle Sprain		Ankle Tendinopathy - Tendinopathy other than Achilles		Charcot Joint	
Phase		Acute	Chronic	Acute	Chronic	Acute	Chronic	Acute	Chronic	Acute	Chronic	Acute	Chronic
<b>ACETIC ACID DERIVATIVES</b>													
<b>diclofenac</b>													
diclofenac potassium	Exempt	C	I	I	I	I		A	I	I	I	I	I
diclofenac sodium	Exempt†												
diclofenac sodium/misoprostol	Exempt									I	I	I	I
etodolac	Exempt	C	I	I	I	I		A	I	I	I	I	I
indomethacin	Exempt	C	I	I	I	I		A	I	I	I	I	I
ketorolac tromethamine	Exempt†	NO	NO	NO	NO	NO		NO	NO	NO	NO	NO	NO
sulindac	Exempt	C	I	I	I	I		A	I	I	I	I	I
tolmetin sodium	Exempt	C	I	I	I	I		A	I	I	I	I	
<b>ANTHRANILIC ACID DERIVATIVES</b>													
meclofenamate sodium	Exempt	C	I	I	I	I		A	I	I	I	I	I
mefenamic acid	Exempt	C	I	I	I	I		A	I	I	I	I	I
<b>CARBOXYLIC ACID DERIVATIVES</b>													
diflunisal	Exempt	C	I	I	I	I		A	I	I	I	I	I
salsalate	Exempt	C	I	I	I	I		A	I	I	I	I	I
<b>COX-2 INHIBITORS</b>													
celecoxib	Exempt	C	I	I	I	I		A	I	I	I	I	I
<b>ENOLIC ACID (OXICAM) DERIVATIVES</b>													
meloxicam	Exempt	C	I	I	I	I		A	I	I	I	I	I
piroxicam	Non-Exempt	NO	NO	NO	NO	NO		NO	NO	NO	NO	NO	NO
<b>NAPHTHYLALKANONE DERIVATIVES</b>													
nabumetone	Exempt	C	I	I	I	I		A	I	I	I	I	I
<b>PROPRIONIC ACID DERIVATIVES</b>													
esomeprazole/naproxen	Non-Exempt	NO	NO	NO	NO	NO		NO	NO	NO	NO	NO	NO
famotidine/ibuprofen	Non-Exempt	NO	NO	NO	NO	NO		NO	NO	NO	NO	NO	NO
fenoprofen calcium	Exempt	C	I	I	I	I		A	I	I	I	I	I
flurbiprofen	Exempt	C	I	I	I	I		A	I	I	I	I	I
flurbiprofen sodium	Exempt												
ibuprofen	Exempt	C	I	I	I	I		A	I	I	I	I	I
ketoprofen	Exempt	C	I	I	I	I		A	I	I	I	I	I
naproxen	Exempt	C/NR*	I/NR*	I	I	I		A	I	I	I	I	I
<b>naproxen sodium</b>													
oxaprozin	Exempt	C	I	I	I	I		A	I	I	I	I	I
<b>SALICYLATES</b>													
aspirin	Exempt					I		I					
choline magnesium trisalicylate	Exempt	C	I	I	I	I		A	I	I	I	I	I
<b>MISCELLANEOUS</b>													
bromfenac sodium	Exempt												

† = Ophthalmic form Exempt; Oral form Non-Exempt

# Current MTUS Formulary

- Only the following five oral NSAIDs on the formulary are “Non-Exempt”
  - diclofenac sodium
  - ketorolac tromethamine
  - piroxicam
  - exomeprazole/naproxen
  - famotidine/ibuprofen
- Two of the generic drug descriptions are not on the Formulary but are salt forms of drugs that are listed
  - diclofenac
  - naproxen sodium
- A detailed Formulary listing currently available dosage forms and strengths for listed (and unlisted) ingredients and their associated RxCUI numbers was also generated

MTUS Drug Ingredient	Generic Name	Reference Brand Name	Exempt/Non-Exempt*	Special Fill	Peri-Op	Drug Class	Dosage Form	Strength	RxCUI
aspirin	aspirin	Bayer	Exempt			Analgesics - NonNarcotic	tablet	325 mg	212033
aspirin	aspirin	Bayer	Exempt			Analgesics - NonNarcotic	tablet	81 mg	243670
aspirin	aspirin	Bayer	Exempt			Analgesics - NonNarcotic	tablet, enteric coated	325 mg	198467
aspirin	aspirin	Bayer	Exempt			Analgesics - NonNarcotic	tablet, enteric coated	81 mg	308416
bromfenac	bromfenac sodium	Prolensa	Exempt			Ophthalmic Agents (NSAID)	solution, ophthalmic	0.07%	1375917
bromfenac	bromfenac sodium	Bromsite	Exempt			Ophthalmic Agents (NSAID)	solution, ophthalmic	0.075%	1790141
bromfenac	bromfenac sodium	Bromday, Xibrom	Exempt			Ophthalmic Agents (NSAID)	solution, ophthalmic	0.09%	578018
celecoxib	celecoxib	Celebrex	Exempt			Analgesics - Anti-Inflammatory (NSAID)	capsule	100 mg	205322
celecoxib	celecoxib	Celebrex	Exempt			Analgesics - Anti-Inflammatory (NSAID)	capsule	200 mg	205323
celecoxib	celecoxib	Celebrex	Exempt			Analgesics - Anti-Inflammatory (NSAID)	capsule	400 mg	349514
celecoxib	celecoxib	Celebrex	Exempt			Analgesics - Anti-Inflammatory (NSAID)	capsule	50 mg	686379
choline magnesium trisalicylate	choline magnesium trisalicylate	Trilisate	Exempt			Analgesics - NonNarcotic (NSAID)	tablet or soution	500mg, 750mg, 500mg/5 ml	215799
diclofenac	diclofenac	Zorvolex				Analgesics - Anti-Inflammatory (NSAID)	capsule	18 mg	1442116
diclofenac	diclofenac	Zorvolex				Analgesics - Anti-Inflammatory (NSAID)	capsule	35 mg	1442128
diclofenac potassium	diclofenac potassium	Zipsor	Exempt			Analgesics - Anti-Inflammatory (NSAID)	capsule	25 mg	858342
diclofenac potassium	diclofenac potassium	Casmbia	Exempt			Analgesics - Anti-Inflammatory (NSAID)	powder for solution	50 mg	859063
diclofenac potassium	diclofenac potassium	Cataflam	Exempt			Analgesics - Anti-Inflammatory (NSAID)	tablet	25 mg	857702
diclofenac potassium	diclofenac potassium	Cataflam	Exempt			Analgesics - Anti-Inflammatory (NSAID)	tablet	50 mg	855942
diclofenac sodium	diclofenac sodium	Voltaren	Non-Exempt			Analgesics - Anti-Inflammatory (NSAID)	tablet, delayed release	25 mg	855644
diclofenac sodium	diclofenac sodium	Voltaren	Non-Exempt			Analgesics - Anti-Inflammatory (NSAID)	tablet, delayed release	50 mg	855906
diclofenac sodium	diclofenac sodium	Voltaren	Non-Exempt			Analgesics - Anti-Inflammatory (NSAID)	tablet, delayed release	75 mg	855926
diclofenac sodium	diclofenac sodium	Voltaren	Non-Exempt			Analgesics - Anti-Inflammatory (NSAID)	tablet, extended release	100 mg	855657

# NSAIDs Product Costs

- Review of costs between products, as was shown in the naloxone review, should be considered
- Historical costs aren't as useful due to the changing rate of reimbursement within the Medi-Cal program
- New Medi-Cal product cost data was used to provide a comparison
- Different cost views of the products
  - Historical dispensing quantities – oral and topical
  - Estimated daily dose – oral products only
  - Estimating topical product daily use is difficult based on the inaccuracy of application by patients
  - Ophthalmic product costs comparisons based on package (bottle size) only

# Historical Dispensing

Generic Name	Dosage Form	Strength	Hx Avg Units/Rx	Lowest Rate	Drug Cost / Rx	No-Sub Rate	FUL	Generic only	Brand only	Higher Cost NDCs
fenoprofen calcium	capsule	200 mg	73	N/A	N/A	N/A	N/A			
fenoprofen calcium	capsule	400 mg	70	3.2141	\$ 224.99	4.7713	0.0000			X
fenoprofen calcium	tablet	600 mg	90	2.8604	\$ 257.44	4.0616	0.0000			
flurbiprofen	tablet	100 mg	86	0.3553	\$ 30.56	0.3553	0.0000			
flurbiprofen	tablet	50 mg		0.2069	N/A	0.2069	0.0000			
ibuprofen	suspension	100 mg/5 ml	707	0.0351	\$ 24.82	0.0351	0.0000			X
ibuprofen	tablet	200 mg	49	0.0293	\$ 1.44	0.0293	0.0000			X
ibuprofen	tablet	400 mg	65	0.0442	\$ 2.87	0.0442	0.0479			X
ibuprofen	tablet	600 mg	53	0.0567	\$ 3.01	0.0567	0.0641			X
ibuprofen	tablet	800 mg	63	0.0651	\$ 4.10	0.0651	0.0673			X
indomethacin	capsule	20 mg		7.2222	N/A	7.2222	0.0000		X	
indomethacin	capsule	25 mg	130	0.1135	\$ 14.76	0.1135	0.1213			
indomethacin	capsule	40 mg		7.2222	N/A	7.0222	0.0000		X	
indomethacin	capsule	50 mg	44	0.1091	\$ 4.80	0.1091	0.0000	X		
indomethacin	capsule, extended release	75 mg	49	0.2802	\$ 13.73	0.2889	0.2802	X		X
indomethacin	suspension	25 mg/5 ml		7.5273	N/A	7.5273	0.0000		X	
ketoprofen	capsule	25 mg	130	1.0816	\$ 140.61	1.0816	0.0000	X		
ketoprofen	capsule	50 mg	50	0.2230	\$ 11.15	0.2230	0.0000	X		
ketoprofen	capsule	75 mg	67	0.2479	\$ 16.61	0.2479	0.0000	X		X
ketoprofen	capsule, extended release	200 mg	37	8.6524	\$ 320.14	8.6524	0.0000	X		

- Blanks are drugs that had no utilization in the data; prices to 4 decimal places as used by Medi-Cal
- N/A prices – drugs did not have a current price (data under review)
- Blanks in both Generic only and Brand only means both available per pricing data
- No-Sub Rate – brand product price if available
- Higher cost NDCs – indicates there may be some NDCs that reflect rates higher than the “lowest” list (data under review)

# Daily Dose

Generic Name	Dosage Form	Strength	Daily Units	Lowest Rate	Lowest Rate / Day	No-Sub Rate	No-Sub Rate/Day
celecoxib	capsule	100 mg	2	0.2188	\$ 0.44	7.3998	14.8000
celecoxib	capsule	200 mg	2	0.1802	\$ 0.36	12.1658	24.3300
celecoxib	capsule	400 mg	1	0.8678	\$ 0.87	18.5795	18.5800
celecoxib	capsule	50 mg	4	0.1597	\$ 0.64	3.5103	14.0400
choline magnesium trisalicylate	tablet	500mg	6	N/A	N/A	N/A	N/A
choline magnesium trisalicylate	tablet	750mg	3	N/A	N/A	N/A	N/A
diclofenac	capsule	18 mg	3	6.8772	\$ 20.63	6.8772	20.6300
diclofenac	capsule	35 mg	3	6.9162	\$ 20.75	6.9162	20.7500
diclofenac potassium	capsule	25 mg	4	11.4296	\$ 45.72	11.4296	45.7200
diclofenac potassium	tablet	25 mg	4	N/A	N/A	N/A	N/A
diclofenac potassium	tablet	50 mg	3	0.4046	\$ 1.21	0.4046	1.2100
diclofenac sodium	tablet, delayed release	25 mg	4	0.9519	\$ 3.81	0.9519	3.8100
diclofenac sodium	tablet, delayed release	50 mg	3	0.1312	\$ 0.39	0.1336	0.4000
diclofenac sodium	tablet, delayed release	75 mg	2	0.1212	\$ 0.24	0.1212	0.2400
diclofenac sodium	tablet, extended release	100 mg	1	1.7173	\$ 1.72	1.7173	1.7200
diclofenac sodium/misoprostol	tablet, enteric coated	50 mg-0.2 mg	3	1.6566	\$ 4.97	8.2065	24.6200
diclofenac sodium/misoprostol	tablet, enteric coated	75 mg-0.2 mg	3	1.8423	\$ 5.53	8.2065	24.6200
diflunisal	tablet	500 mg	3	1.2403	\$ 3.72	1.2403	3.7200

- Estimated daily dose
  - Dosing for some drugs varies significantly depending on use
  - Daily doses shown at or below allowed maximum for each drug
- Lowest and No-Sub rates per day calculated for comparative purposes

# Ophthalmics and Topicals

Generic Name	Dosage Form	Strength	Avg Units/Rx (mfr pkg size)	Lowest Rate	Drug Cost/Rx	No-Sub Rate	FUL	Generic only	Brand only	Higher Cost NDCs
bromfenac sodium	solution, ophthalmic	0.07%	3.0	85.3149	\$ 255.94	85.3149	0.0000		X	
bromfenac sodium	solution, ophthalmic	0.075%	5.0	49.8920	\$ 249.46	49.8920	0.0000		X	
bromfenac sodium	solution, ophthalmic	0.09%*	1.7	66.0809	\$ 112.34	66.0809	0.0000	X		
diclofenac sodium	solution, ophthalmic	0.1%	2.5	1.9836	\$ 4.96	1.9836	0.0000	X		
diclofenac sodium	solution, ophthalmic	0.1%	5.0	2.4407	\$ 12.20	2.4407	0.0000	X		
flurbiprofen sodium	solution, ophthalmic	0.03%	2.5	1.8020	\$ 4.51	1.8020	0.0000	X (single)		
ketorolac tromethamine	solution, ophthalmic	0.4%	5.0	9.8800	\$ 49.40	53.9340	0.0000			
ketorolac tromethamine	solution, ophthalmic	0.45%	12.0	10.2984	\$ 123.58	10.2984	0.0000			
ketorolac tromethamine	solution, ophthalmic	0.5%	3.0	1.6947	\$ 5.08	1.6947	0.0000	X		
ketorolac tromethamine	solution, ophthalmic	0.5%	5.0	1.5867	\$ 7.93	52.4620	0.0000			
ketorolac tromethamine	solution, ophthalmic	0.5%	10.0	1.6555	\$ 16.56	1.6555	0.0000	X		

Generic Name	Dosage Form	Strength	Avg Units/Rx (mfr pkg size)	Lowest Rate	Drug Cost/Rx	No-Sub Rate	FUL	Generic only	Brand only	Higher Cost NDCs
diclofenac sodium	gel, topical	1%	100	0.2376	\$ 23.76	0.5183	0.4364	X		
diclofenac sodium	gel, topical	3%	100	0.6766	\$ 67.66	0.6766	1.3355	X		
diclofenac sodium	solution, topical	1.5%	150	0.1914	\$ 28.71	11.1576	0.4620			
diclofenac sodium	solution, topical	2%	112	21.3597	\$ 2,392.29	21.3597	0.0000		X	
ketorolac tromethamine	nasal spray	15.75mg/spray	1	357.3280	\$ 357.33	357.3280	0.0000		X	

# Committee Discussion

- NSAIDs Considerations
  - Inclusion of diclofenac and naproxen sodium onto MTUS Formulary
  - Should there be changes to Exempt or Non-Exempt status
    - By drug
    - By dosage form
    - By strength
  - Cost considerations (relative value)
- Other discussion points / items to consider

# Process Discussion

- Value of information presented
- Process recommendations
- Information members like, dislike, additional needs
- Next drugs/categories to consider – how to choose
  - Removal of drugs identified as Physician Administered
- Other issues to consider
  - Next meeting – Special Fill and Peri-Op

# Public Comments

# Review of Recommendations

# Adjournment